FDA Approved: DAYVIGO — Supplemental Application (Eisai Inc.)

View source ↗

Summary

This FDA page documents Eisai Inc.'s supplemental application for Dayvigo (lemborexant), seeking to modify or expand its labeling for the treatment of insomnia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Insomnia

Drugs mentioned

• Dayvigo (lemborexant)

Snippet

SUPPL AP for DAYVIGO (LEMBOREXANT)